针对危重创伤患者目标性正常氧疗的多中心整群随机阶梯楔形实施试验:避免过度氧疗策略(SAVE-O2)试验的研究方案与统计分析计划
SAVE-O2是一项在美国8家一级创伤中心开展的多中心整群随机阶梯楔形实施试验,评估多模式干预以提高危重创伤患者对目标性正常氧疗(SpO2 90-96%或PaO2 60-100 mmHg)的依从性。主要结局为无补充氧天数,次要结局包括至第90天院内死亡、至第90天无住院天数、至第28天无呼吸机天数等。该试验将明确多模式干预能否安全减少危重创伤患者对浓缩氧的需求。
要点
- 目标性正常氧疗定义为SpO2 90-96%或PaO2 60-100 mmHg。
- 主要结局为无补充氧天数,即存活且未使用补充氧的天数。
- 试验在美国8家一级创伤中心开展,采用整群随机阶梯楔形实施设计。
核心结论
- SAVE-O2将确定旨在提高目标性正常氧疗依从性的多模式干预能否安全减少危重创伤患者对浓缩氧的需求。
研究设计与样本
- 多中心整群随机阶梯楔形实施试验,在美国8家一级创伤中心评估针对危重创伤患者目标性正常氧疗的多模式干预。
- 所有中心均从常规诊疗的对照阶段开始,达到随机分配的时间点后进入为期1个月的培训期(不纳入数据收集),随后在试验剩余期间保持干预阶段。
- 每个医院均贡献实施前(对照)和实施后(干预)数据。
主要发现
- 主要结局为无补充氧天数,定义为存活且未使用补充氧的天数。
- 次要结局包括至第90天院内死亡、至第90天无住院天数、至第28天无呼吸机天数(VFD)、达到室内空气的时间、格拉斯哥结局评分(GOS)以及接受补充氧的时长。
关键数值与推荐
- 目标性正常氧疗的氧合目标为SpO2 90-96%或PaO2 60-100 mmHg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Targeted normoxia (SpO2 90-96% or PaO2 60-100 mmHg) may help to conserve oxygen and improve outcomes in critically ill patients by avoiding potentially harmful hyperoxia. However, the role of normoxia for critically ill trauma patients remains uncertain. The objective of this study is to describe the study protocol and statistical analysis plan for the Strategy to Avoid Excessive Oxygen for Critically Ill Trauma Patients (SAVE-O2) clinical trial. METHODS: Design, setting, and participants: Protocol for a multicenter cluster randomized, stepped wedge implementation trial evaluating the effectiveness of a multimodal intervention to target normoxia in critically ill trauma patients at eight level 1 trauma centers in the USA. Each hospital will contribute pre-implementation (control) and post-implementation (intervention) data. All sites will begin in the control phase with usual care. When sites reach their randomly assigned time to transition, there will be a one-month training period, which does not contribute to data collection. Following the 1-month training period, the site will remain in the intervention phase for the duration of the trial. MAIN OUTCOME MEASURES: The primary outcome will be supplemental oxygen-free days, defined as the number of days alive and not on supplemental oxygen. Secondary outcomes include in-hospital mortality to day 90, hospital-free days to day 90, ventilator-free days (VFD) to day 28, time to room air, Glasgow Outcome Score (GOS), and duration of time receiving supplemental oxygen. DISCUSSION: SAVE-O2 will determine if a multimodal intervention to improve compliance with targeted normoxia will safely reduce the need for concentrated oxygen for critically injured trauma patients. These data will inform military stakeholders regarding oxygen requirements for critically injured warfighters, while reducing logistical burden in prolonged combat casualty care. TRIAL REGISTRATION: ClinicalTrials.gov NCT04534959 . Registered September 1, 2020.
引用
- Dylla L, Douin DJ, Anderson EL, et al. A multicenter cluster randomized, stepped wedge implementation trial for targeted normoxia in critically ill trauma patients: study protocol and statistical analysis plan for the Strategy to Avoid Excessive Oxygen (SAVE-O2) trial. Trials. 2021. PMID: 34749762. doi:10.1186/s13063-021-05688-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。